Birmingham uses OMNI-Lab for baby tests

  • 9 September 2009

Birmingham Children’s Hospital NHS Foundation Trust is using a subset of OMNI-Lab to manage the bloodspot screening tests taken from 70,000 newborn infants across the West Midlands each year.

The heelprick tests are used to screen for five serious diseases, as part of the UK Newborn Screening Programme, which is carried out by centres of excellence across the UK.

Another of these centres, Great Ormond Street Children’s Hospital, already uses OMNI-Lab NewBorn Screening, which manages the process from receipt of blood spot card to results and statistical reporting.

Paul Griffiths, director of newborn screening at Birmingham Children’s Hospital, said it had been confident that Integrated Software Solutions Limited could adapt its software to the hospital’s particular requirements.

In particular, the hospital wanted to develop electronic links to various child health systems, so much of the testing process could be automated; saving time and potential errors that could creep in from the typing and retyping of notes.

“They have always been willing to try things for us and were particularly helpful when we needed to convert 25 years of historic data and bring it into a new system of coding for reporting results; a massive undertaking that they managed for us with complete success,” Griffiths added.

Link:

Integrated Software Solutions

Subscribe To Our Newsletters

Subscribe to our newsletter

Subscribe To Our Newsletter

Related News

UK Biobank to get access to GP patient data for research

UK Biobank to get access to GP patient data for research

The government will grant approval for UK Biobank researchers to access coded GP patient data for research purposes.
NHS App to become national channel for the ‘shift to prevention’ 

NHS App to become national channel for the ‘shift to prevention’ 

The NHS App is becoming the national channel for preventative healthcare, said Rachel Hope, director of digital prevention services at NHSE.
The case for scaling AI in screening for disease

The case for scaling AI in screening for disease

We must understand what responsible AI adoption requires for the NHS, writes Prof Alicja Rudnicka of City St George’s, University of London